natgillin/translations-raw huggingface dataset:
contacting the crude compound of formula (VI) with a 3-pyridyl borane derivative under Suzuki cross-coupling conditions to give the abiraterone 3B-formyloxy ester of formula 
stavljanje sirovog spoja formule (VI) u kontakt s derivatom 3-piridilborana u uvjetima Suzukijevog ukriženog konjugiranja kako bi se dobio 3B-formiloksi ester abiraterona formule [image];
Method according to any one of claims 1 to 7, characterized in that the immunoglobulin solution comprises a sugar and a surfactant and has a concentration of 125 mg/ml or more and the applying to the combination of the filter is by applying a pressure of 0.75 bar or less. 
Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time, da otopina imunoglobulina sadrži šećer 1 tenzid i ima koncentraciju od 125 mg/ml ili više, te se nanošenje na kombinaciju filtera vrši primjenom tlaka od 0,75 bara ili manje.
The antisense oligonucleotide of claim 4, wherein the antisense oligonucleotide is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide. 
Antisens oligonukleotid u skladu sa zahtjevom 15, naznačen time što navedeni antisens oligonukleotid je kemijski vezan na jedan ili više ostataka ili konjugata koji poboljšavaju aktivnost, raspodjela po stanici, ili unos u stanicu antisens oligonukleotida.
The engine of 24 wherein substantially at least 10% of the total combustion event occurs prior to the crossover valve closing. 
Motor (100) iz patentnih zahtjeva 1 i 2, naznačen time što se najmanje približno 10% od ukupnog izgaranja dogodi prije zatvaranja prijelaznog ventila (150).
The process according to claim 7, wherein said virus is selected from the group comprising poxviruses, orthomyxoviruses, paramyxoviruses, herpes viruses, hepadnaviruses, adenoviruses, parvoviruses, reoviruses, circoviruses, coronaviruses, flaviviruses, togaviruses, birnavriruses and retroviruses. 
Postupak prema zahtjevu 10, gdje se taj virus izabire iz grupe koja obuhvaća pox viruse, ortomiksoviruse, paramiksoviruse, herpes viruse, hepa dna viruse, adenoviruse, parvoviruses, reoviruse, cirkoviruse, koronaviruse, flaviviruse, togaviruse, birnaviruse i retroviruse.
enhances or mimics the action of acetylcholine, or 
(D pojačava ili oponaša djelovanje acetilkolina, ili
a first component which comprises 15 to 30 wt % of alkanolamine, wherein the alkanolamine comprises mono-, di-, and/or triethanolamine, and 10 to 30 wt % of complexing agent; and 
prvu komponentu koja sadrži najmanje 15% mase alkanolamina i najmanje 10% mase kompleksirajućeg sredstva;
A respiratory syncytial virus (RSV) fusion (F) protein encoded by a nucleic acid having the sequence of SEQ ID NO:7. 
Respiratorni sincicijski virus (RSV) fuzijski (F) protein koji sadrži:
A dispenser according to claim 1, wherein the engaging portion comprises one or more teeth arranged to contact an inner circumferential surface of the first ring member. 
Dispenzer u skladu sa patentnim zahtjevom 18, gdje dio (1620) za angažiranje mehanizma za ograničavanje sadrži jedan ili više zuba koji su razmješteni da kontaktiraju unutarnju perifernu površinu prvog prstenastog elementa (202, 1610).
Accordingly, the present invention relates to a pharmaceutical combination comprising as components 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol of formula (I) optionally in form of one of its pure stereoisomers, in particular an enantiomer or a diastereomer, a racemate or in form of a mixture of its stereoisomers, in particular enantiomers and/or diastereomers in any mixing ratio, or any corresponding acid addition salt thereof, and 
(a) barem jedan 3-(3-Dimetilamino-1-etil-2-metil-propil)-fenol sa formulom (I), il proizvoljno u obliku jednog od njegovih stereoizomera, naročito enantiomera ili diastereomera, racemata ili u obliku smjese njegovih stereoizomera, naročito enantiomera i/ili diastereomera u bilo kojem omjeru miješanja, ili bilo koja odgovarajuća kisela adicijska sol, te (b) barem jedno antiepileptičko sredstvo odabrano iz skupine koja sadrži topiramat, lamotrigin, karbamazepin, lakozamid, levetiracetam i retigabin.
allowing for depletion of the injected oxygen within the contaminated subsurface environment, and 
(1i) omogućavanje osiromašivanja ubrizganog kisika unutar kontaminiranog podzemnog okoliša,
Use according to any of the claims 1-4, wherein the fatty acid ester group is an ester of a straight, branched, saturated or unsaturated fatty acid with a chain length of 4 to 20 carbon atoms, preferably 6 to 18, more preferably 8 to 16 carbon atoms, most preferably 10 to 14 carbon atoms, highly preferred 12 carbon atoms. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačena time što je esterska skupina masne kiseline ester nerazgranate, razgranate, zasićene ili nezasićene masne kiseline s duljinom lanca od 4 do 20 atoma ugljika, po mogućnosti 6 do 18, poželjnije 8 do 16 atoma ugljika, najpoželjnije 10 do 14 atoma ugljika, krajnje poželjno 12 atoma ugljika.
The composition according to any of the previous claims further comprising Mg(OH)2 in a molar ratio between 2/3 and 2/5, expressed as the molar ratio of drug to Mg(OH)2. 
Sastav u skladu s bilo kojim od prethodnih zahtjeva nadalje sadržava Mg(OH)2 u molarnom omjeru između 2/3 12/5, izražen kao molarni omjer lijeka naspram Mg(OH)2.
Preferably, the width of the packaging is between 134 mm and 138 mm, and the length of the packaging is between 188 mm and 194 mm when packaging is in a closed condition. 
Poželjno je da je širina pakiranja između 134 mm i 138 mm, i da je dužina pakiranja između 188 mm i 194 mm, kada je pakiranje u zatvorenom stanju.
In other instances, the chelating agent is present at a molar excess to that of the bisphosphonate. The chelating agent in such instances is present in at least a 2:1 molar ratio of the chelating agent to bisphosphonate. 
Cc) enteričkog sloja koji služi za oslobađanje bisfosfonata i EDTA u nižem gastrointestinalnom traktu sisavaca; naznačen time da je molarni omjer dinatrijeve EDTA u bisfosfonatu najmanje 2:1.
Beta-blockers are used for the treatment of high blood pressure, control of angina, arrhythmia, post myocardial infection, heart failure, migraine or essential tremor. 
Beta-blokatori se rabe za liječenje visokog krvnog pritiska, kontrolu angine, aritmije, post miokardijskih infekcija, zatajenja srca, migrene ili osnovnih drhtavica.
R1-R2 are independently selected from hydrogen, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, and C3-8-cycloalk(en)yl-C1-6(en/yn)yl or R1 and R2 together with the nitrogen form a 4-7 membered ring containing zero or one double bond, optionally said ring in addition to said nitrogen comprises one further heteroatom selected from nitrogen, oxygen and sulphur; 
- R-R? se nezavisno biraju iz vodika, C,.4-alk(en/in)il, C;_.g-cikloalk(en)il i C3 g-cikloalk(en), ili R!iR? zajedno s dušikom tvore 4-7-člani prsten koji sadrži nula ili jednu dvostruku svezu a, opcionalno, rečeni prsten, uz rečeni
The composition for use according to any one of claims 1-8, wherein said composition is lyophilized. 
Sastav za upotrebu prema bilo kojem od patentnih zahtjeva 1-8, pri čemu je navedeni sastav liofilizirani.
The method of claim 8, wherein the suitable salt formed is the hydrogen fumarate salt or the hydrogen maleate salt of Compound VII. 
22. Postupak prema zahtjevu 21, gdje je nastala sol vodik fumarat ili vodik maleat Spoja VII.
Further especially preferred compositions according to the invention comprise as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide (compound A-1.1) and as component (B) a compound selected from azoxystrobin, picoxystrobin, bixafen, fludioxonil, fenpropidin, difenoconazole, cyprodinil, mandipropamid, chlorothalonil, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
The method as in claim 1 or 2, wherein the feeding steps respectively comprise continuously feeding the predispersion and the remaining portion of the viscous material into the first container; and the method further comprises intermittently or continuously removing a reaction product thereof from the first container. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da koraci dodavanja redom sadrže kontinuirano dovođenje predisperziju i preostali dio viskoznog materijala u prvi spremnik; a navedeni postupak dodatno obuhvaća povremeno ili kontinuirano uklanjanje njegovog reakcijskog proizvoda iz prvog spremnika.
Preferably, the organogelator comprises a hydrazide unit when n and m have a value of 0. 
organogelator sadrži hidrazidnu jedinicu kada n i m imaju vrijednost 0; ili
optionally, drying the suspension obtained following steps a) or b); 
€) po izboru, sušenje suspenzije dobivene u koracima a) ili b);
The device as claimed in claim 11, characterized in that at least one horizontal top cross member (13) of the modular elements comprises means for heating the platform. 
Uređaj u skladu s prethodnim patentnim zahtjevom, naznačen time što najmanje jedna vodoravna gornja traverza (13) modularnih elemenata sadrži sredstvo za grijanje platforme.
The sports apparatus of claim 1, wherein the convex top surface (15) comprises a spatial curve consisting of several curved sections. 
Sportski uređaj u skladu s patentnim zahtjevima 1 ili 2, naznačen time što udubljena gornja površina (15) sadrži prostornu krivulju, koja se sastoji od više zakrivljenih dijelova.
The CD19xCD3 bispecific single chain antibody construct for the use of any one of claims 1 to 12, wherein the CD19xCD3 bispecific single chain antibody construct is to be administered in a daily dose of 15µg, 30µg, 60µg, or 90µg per square meter patient body surface area. 
CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt treba primijeniti u dnevnoj dozi od 15 µg, 30 µg, 60 µg ili 90 µg po kvadratnom metru površine pacijentovog tijela.
The pharmaceutical composition for use according to claim 18, wherein said arthritides and connective tissue disease is selected from the group consisting of reactive arthropathies, postinfective arthropathies, inflammatory polyarthropathies, systemic connective tissue disorders, inflammatory spondylopathies, myositis, synovitis, Reiter's disease, seropositive rheumatoid arthritis, rheumatoid arthritis, extraarticular rheumatoid disease, psoriatic and enteropathic arthropathies, juvenile arthritis, arthritis, polyarteritis nodosa and related conditions, necrotizing vasculopathies, dermatopolymyositis, systemic sclerosis, systemic involvement of connective tissue, ankylosing spondylitis and inflammatory spondylopathies. 
Farmaceutski pripravak za uporabu prema zahtjevu 18, gdje su spomenuti artritis i bolest vezivnog tkiva izabrani iz skupine koja se sastoji od reaktivnih artropatija, postinfektivnih artropatija, upalnih poliartropatija, sustavnih bolesti vezivnog tkiva, upalnih spondilopatija, miozitisa, sinovitisa, Reiterove bolesti, seropozitivnog reumatoidnog artritisa, reumatoidnog artritisa, ekstraartikularne reumatske bolesti, psorijatskih 1 enteropatskih artropatija, juvenilnog artritisa, artritisa, poliarteritisa nodoze i srodnih stanja, nekrotizirajućih vaskulopatija, dermatopolimiozitisa, sustavne skleroze, sustavnog zahvaćenja vezivnog tkiva, ankilozantnog spondilitisa i upalnih spondilopatija.
an antifactor Xa activity of less than 10 IU/mg; and 
(ii) aktivnost antifaktora Xa manju od 10 IU/mg; i
there are also fed into said mixing reactor 3 dosed quantities of the reactants that are source of N, P₂O₅ and K₂O, e.g. 
također i odmjerene količine reagenata, koji su izvori N, P205 i K,0, npr.
is selected from the group consisting of H, fluoro, chloro, C1-C3 alkyl, hydroxy-C1-C3-alkyl, and halo-C1-C2-alkyl, which contains 1 to 5 halogens; 
je odabran od grupe koja se sastoji od C1-C4 alkila, halo, i halo-C1-C2-alkila, koji sadrži 1 do 5 halogena, gdje je halo F ili Cl;
A pharmaceutical composition comprising an effective amount of a compound, stereoisomer, tautomer, oxide, ester, or pharmaceutically acceptable salt thereof of claim 1 or 60, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj, njegov stereoizomer, tautomer, solvat ili oksid, ili njegovu farmaceutski prihvatljivu sol u skladu s bilo kojim od zahtjeva 1 do 4, zajedno s farmaceutski prihvatljivim nosačima.
instructions for (i) use of the solution or (ii) reconstitution and/or use of the lyophilized formulation. 
opcionalno, upute za (i) uporabu otopine ili (ii) rekonstituciju i/ili uporabu liofilizirane formulacije.
Description of the sequences: 
Broj objave europskog patenta:
the amphiregulin, the epidermal growth factor and the HER2 marker gene, and 
amfiregulin-marker-genom, marker-genom faktora epidermalnog rasta i marker-genom alfa faktora transformacije rasta,
EPMATHMARKEREP EPMATHMARKEREP EPMATHMARKEREP are solved through harmonic analysis. The balanced phacoemulsification tip of claim 1, wherein a proximal end of the tip includes a conical portion and wherein a length of the conical portion is selected to increase twisting vibrations of the tip during ultrasonic torsional vibrations to provide a greater lateral displacement at the distal end point of the tip. 
Fakoemulzifikacijski vrh prema zahtjevu 3, naznačen time, daje proksimalni kraj (114) od vrha koji uključuje stožasti odsječak i pri čemu je duljina stožastog odsječka odabrana kako bi povećala zavrnute vibracije od vrha za vrijeme ultrazvučnih torzijskih vibracija, u svrhu postizavanja većeg bočnog premještanja na točki distalnog kraja (106) od vrha.
The taper of container 1100 creates a dome-like structure that facilitates the blending of the contents of container 1100 . FIGS. 
Suženje posude 1100 čini oblik kupole koji olakšava miješanje sadržaja u posudi 1100.
The composition according to any one of claims 8-11, wherein the fatty acid or derivative thereof has a carbon chain length of not more than 22 carbon atoms. 
Sastav prema bilo kojem zahtjevu 8-11, naznačen time, da masna kiselina ili njezin derivat ima ugljikov lanac duljine od najviše 22 ugljikova atoma.
A process for manufacture of compound with Formula I comprises the following steps: 
Proces za pripremu spoja s formulom I obuhvaća slijedeće korake: a) spoj s formulom II
According, to a particularly preferred embodiment, the metallic pigments used in the granules according to the invention are titanium dioxide-based pigments present on the surface of said granule. 
Granula prema zahtjevu 1 ili 2, naznačena time, da metalna pigmentacijska sredstva su pigmenti na bazi titanij dioksida, a nalaze se na površini spomenute granule.
Total Number of Animals: 28 
Broj objave europskog patenta:
formoterol, or a salt thereof or a solvate of said salt, at a dosage in the range of from 1 to 25 µg per actuation; 
formoterol ili njegovu sol ili solvat rečene soli u dozi u rasponu od 1 do 25 ug po aktiviranju; propelant HFA;
Another object of the present invention is to provide a waterproof sheet that ensures that the packaged food is protected against light and infrared radiation but also ensures that the aluminum does not migrate from the sheet. 
Drugi cilj predloženog izuma je osigurati vodonepropusnu foliju koja osigurava da je zapakirana hrana zaštićena od svjetla 1 infracrvenog zračenja, ali koja također osigurava da aluminij ne migrira iz folije.
Method for applying at least one chemical substance and/or preparation to at least one tree and/or palmaceae characterized in that it comprises: 
Metoda za primjenu najmanje jedne kemijske tvari i/ili pripravka na najmanje jedno stablo i/ili palmu obuhvaća postojanje naprave iz bilo kojeg od patentnih zahtjeva 1 do 4 i:
• applying wear resistant particles (15) on the surface (2), 
. nanošenje čestica otpornih na habanje (15) na površinu (2),
The method according to claim 6, wherein the catalyst essentially consists of alumina in the Y-form and heterogeneously distributed palladium. 
Metoda u skladu s patentnim zahtjevom 6, pri čemu katalizator u osnovi sadrži aluminij oksid u Y-obliku i heterogeno raspodijeljen paladij.
preparation of #2 Extract: Radix Paeoniae alba is added with 3∼6 fold of 50∼80% ethanol, soaked, extracted by using heating refluxing for 2∼3 times, the first time for 0.5∼2.5 hours, the second and/or third time for 0.5∼2 hours, and filtered; and the ethanol is recovered and concentrated until the relative density is 1.10∼1.35 at 55∼65°C to give #2 Extract for later use; 
Priprema ekstrakta br. 2: u Radix Paeoniae alba se dodaje 3 do 6 puta veća količina 50 do 80 % etanola, namoči se, ekstrahira se uz refluks i zagrijavanje 2 do 3 puta, prvi put 0,5 do 2,5 sati, drugi 1 / ili treći put u trajanju od 0,5 do 2 sata 1 filtrira; i etanol se izdvaja i koncentrira do relativne gustoće 1,10 - 1,35 na 55 do 65 "C da se dobije ekstrakt br. 2 za kasniju uporabu;
● said culturing is effected until said adherent cells reach at least 60 % confluence and/or 
dodatno sadrži izoliranje navedenih adherentnih stanica korištenjem probavnog enzima kao što je kolagenaza; i/ili
reacting the compound of formula (2a) or a salt thereof, with chlorosulfonic acid to form a compound of formula (IV): or a salt thereof; and 
reakciju spoja formule (2a): ili njegove soli, sa sredstvom za sulfoniranje, da se dobije spoj formule (IV): ili njegova sol;
The recombinant virus of any one of claims 1 or claim 2, which expresses HSV-2 gB under the control of the tetO-bearing HSV or hCMV immediate early promoter. 
Rekombinantni virus iz bilo kojeg od patentnih zahtjeva 1 ili 2, koji eksprimira HSV-2 gB pod kontrolom izravnog ranog promotora HSV ili hCMY koji sadrži tet-O.
Plasma is obtained after centrifugation (1200 g 15 min) and immediately processed. 
Plazma je dobivena nakon centrifugiranja (1200 g 15 minuta) i odmah je nastavljen postupak.
Being that threshold not a fixed value for comparison stored a priori in unit 50 but the result of a pre-set current that really must be detected by the GFCI 1 in the initialisation phase, the GFCI 1 assures a check even for an actually too low operating threshold for the GFCI 1. 
S obzirom da donja vrijednost praga za komparaciju koja je a priori spremljena u jedinici 50 nije fiksna vrijednost, nego rezultat prethodno postavljene struje koju GFCI 1-sklop stvarno mora detektirati u fazi pokretanja, GFCI 1 osigurava provjeru čak i za prenizak prag.
increasing the temperature of the frozen G-CSF composition of step (c) to a temperature within the range of from 2° C. to 8° C. over a time which allows the composition to thaw and to obtain a liquid composition having a G-CSF content of at least 95% of the G-CSF content of the composition provided in step (a). 
(d) povećanje temperature zamrznutog G-CSF-sastava iz koraka (c) na temperaturu u rasponu od 2%C do 8"C u vremenskom periodu namještenom tako da dopusti sastavu odmrzavanje te za dobivanje tekućeg sastava koji ima sadržaj G-CSF od najmanje 95% sadržaja sastava pribavljenog u koraku (a).
fluoxetine, fluvoxamine, paroxetine, sertraline or escitalopram, or a pharmaceutically acceptable salt thereof; or 
fluoksetina, fluvoksamina, paroksetina, sertralina ili escitaloprama ili njihovih farmaceutski prihvatljivih soli; ili
A compound of formula Xlla wherein X is oxygen or sulfur. 
Spoj s formulom XIIa [image] naznačen time da X je kisik ili sumpor.
Number of units per flask: 1 
Broj objave europskog patenta:
In more specific embodiments of the foregoing, Q1 is: wherein: R1 is hydrogen; R2 is hydrogen; and each R3 is hydrogen. 
£ E je" x Kn, Bea 1 pri čemu: R, je vodik; R2 je vodik i svaki R; je vodik.
In addition to the foregoing, the compounds of the invention are also indicated for use in the therapy of septic shock, e.g., as anti-hypovolaemic and/or anti-hypotensive agents; in the treatment of inflammatory bowel disease; cerebral oedema; headache; migraine; inflammatory skin disease, such as eczema and psoriasis; inflammatory disorders of the gut, e.g., irritable bowel syndrome; Crohn's disease; ulcerative colitis; and cystitis, e.g., interstitial cystitis, nephritis and uveitis. 
Dodatno uz gore navedeno, spojevi formula (I) i (Ia) mogu se također propisati za upotrebu u terapiji septičkog šoka, npr. kao anti-hipovolemiska 1/ili anti-hipotenzivna sredstva; u liječenju upalne bolesti crijeva; cerebralnog edema; glavobolje; migrene; upalne kožne bolesti, kao što su ekcem i psorijaza; upalni poremećaji crijeva, npr. sindrom nadražcnih crijeva; Crohnova bolcst; ulecrativni kolitis; 1 cistitis, npr. intersticijalni cistitis, nefritis i uvcitis.
The device according to any of the claims from 2 to 5, wherein said end member (8) comprises a latch element (5) for locking with said engagement means (6), said latch element being supported at a free end of said member, opposite with respect to an end of connection with said rod (4). 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da navedeni krajnji član (8) ima zasunski element (5) za zaključavanje s navedenim sredstvima za spajanje (6), pri čemu je navedeni zasunski element poduprt na slobodnom kraju navedenog člana, na suprotnom kraju u odnosu na spoj s navedenom šipkom
A pharmaceutical composition comprising a polymorph according to any one of claims 1 to 12 for use in the treatment of anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, cognitive memory disorders, Parkinsons Disease, ADHD, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, stroke and also disorders associated with spinal trauma and/or head injury, IBS or obesity. 
Farmaceutski pripravak koji sadrži polimorf prema bilo kojem od patentnih zahtjeva 1 do 12, namijenjen upotrebi u liječenju anksioznosti, depresije, epilepsije, opsesivno-kompulzivnih poremećaja, migrene, poremećaja kognitivnog pamćenja, Parkinsonove bolesti, ADHD, poremećaja spavanja, poremećaja hranjenja, poput anoreksije i bulimije, napadaja panike, ustezanja od zloupotrebe narkotika, poput kokaina, etanola, nikotina i benzodiazepina, shizofrenije, inzulta, a također i poremećaja povezanih s ozljedama kralježnice 1(li) glave, IBS ili pretilosti.
All the needles of the machine are made to knit at the second and fourth drops, forming drop stitches and producing plain knitting. 
Sve igle stroja su izrađene za pletenje na drugom i četvrtom transporteru, tvoreći redove očica i stvarajući ravno pletivo.
n represents a number of X2 and is an integer of 0 to 3; 
n predstavlja broj skupina od X2, koji je cijeli broj od 0 do 3.
The device of claim 1, wherein the at least one connector element includes connecting structure configured to support the plural ones of the cages in a non-coplanar, face-on manner as a stack, in which stack the peripheral regions of the mutually adjacent cages form a corrugated envelope. 
Uređaj iz zahtjeva 1, unutar kojeg najmanje jedan spojni element uključuje priključnu strukturu koja je postavljena kako bi podržavala veći broj kaveza kao skup, unutar kojeg periferna područja susjednih kaveza tvore valoviti omotač.
The method according to claim 1, wherein lapatinib, or a pharmaceutically acceptable salt or composition thereof, is administered to said human as monotherapy. The method according to claim 1, wherein said lapatinib, or a pharmaceutically acceptable salt or composition thereof, is co-administered with at least one other anti-cancer agent. 
Lapatinib ili njegova farmaceutski prihvatljiva sol ili njihov sastav, koji/koja se upotrebljava u liječenju ljudi od raka prema zahtjevu 1 ili zahtjevu 2, naznačen/a time, da se navedeni lapatinib ili njegova farmaceutski prihvatljiva sol ili njihov sastav, daje zajedno s najmanje jednim nekim drugim sredstvom protiv raka.